Ajinkya Patil

Employment

• Pfizer Inc Senior Scientist
  2023 - Present

Education

• Harvard University PhD in Virology
  2019 - 2023
• Northwestern University Master of Biotechnology Program (MBP)
  2013 - 2015
• RV College of Engineering BE Biotechnology
  2009 - 2013

Projects & Funding

Projects & funding information is unavailable.

Publications (14)

• Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas
  2025 DOI: 10.1101/2025.10.13.681937
  +Save
• Cytotoxicity of Activator Expression in CRISPR-based Transcriptional Activation Systems
  2024 DOI: 10.1101/2024.09.23.614524
  +Save
• A disordered region controls cBAF activity via condensation and partner recruitment
  Cell 2023 DOI: 10.1016/j.cell.2023.08.032
  +Save
• DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner
  PLoS Biology 2023 DOI: 10.1371/journal.pbio.3002097
  +Save
• Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection
  Nature Genetics 2023 DOI: 10.1038/s41588-023-01307-z
  +Save
• Kinase-independent activity of DYRK1A promotes viral entry of highly pathogenic human coronaviruses
  bioRxiv 2022 DOI: 10.1101/2022.09.13.507833
  +Save
• Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection
  Cell 2021 DOI: 10.1016/j.cell.2020.10.028
  +Save
• The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation
  Science 2021 DOI: 10.1126/science.abg5784
  +Save
• Genome-wide CRISPR Screens Reveal Genetic Mediators of Cereblon Modulator Toxicity in Primary Effusion Lymphoma
  bioRxiv 2019 DOI: 10.1101/619312
  +Save
• Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma
  Blood Advances 2019 DOI: 10.1182/bloodadvances.2019031732
  +Save